Skip to main content
SAM CHUN DANG PHARM CO. LTD logo

SAM CHUN DANG PHARM CO. LTD — Investor Relations & Filings

Ticker · 000250 ISIN · KR7000250001 KO Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2019-03-26 M&A Activity
Country KR South Korea
Listing KO 000250

About SAM CHUN DANG PHARM CO. LTD

http://www.scd.co.kr/english/scd/index.…

SAM CHUN DANG PHARM CO. LTD. is a pharmaceutical company focused on the development, manufacturing, and sale of medications. The company specializes in ophthalmic products, establishing itself as a significant player in the generic eye care market. Its portfolio also extends to other therapeutic areas, including antibiotics and medications for the circulatory system. The company produces a range of ethical (prescription) and over-the-counter (OTC) drugs in both sterile and non-sterile forms. Manufacturing operations adhere to international quality standards, holding both US and EU Good Manufacturing Practice (GMP) certifications.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(황반변성치료제(주성분: Aflibercept) 바이오시밀러 SCD411의 일본 독점판매권 및 공급계약 체결)
M&A Activity Classification · 95% confidence The document is a regulatory filing from Samchundang Pharm regarding a major business decision: the signing of an exclusive sales and supply agreement for a biosimilar drug (SCD411) with SENJU Pharmaceutical. This type of disclosure, which details material contracts, licensing agreements, and financial milestones, is classified as a general regulatory filing (RNS) in the absence of a more specific category like M&A (which usually refers to corporate mergers/acquisitions) or a specific financial report.
2019-03-26 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (Annual General Meeting). It details the approval of financial statements, dividend resolutions, and the election of directors. This falls directly under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports the outcome of shareholder votes at the AGM.
2019-03-15 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Samchundang Pharm. It contains the auditor's opinion, financial statements (consolidated and separate), and key financial metrics for the fiscal year. While it provides financial data, it is a specific regulatory disclosure of the audit report results rather than the full 10-K annual report itself. In the context of Korean regulatory filings (DART), this is classified as an Audit Report/Information filing. FY 2018
2019-03-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 98% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. This type of filing is specifically used to report changes in shareholdings by insiders or major shareholders. In the provided taxonomy, 'Director's Dealing' (DIRS) is the category for reports of personal share transactions by company directors and executives, and 'Major Shareholding Notification' (MRQ) covers changes in significant ownership. Given the document explicitly identifies the reporter as a '10% or more shareholder' (10%이상주주) and details the acquisition of convertible bonds and bonds with warrants, it fits the 'Major Shareholding Notification' category.
2019-02-22 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Samchundang Pharm. It outlines the date, location, and agenda items (such as approval of financial statements, appointment of directors, and remuneration limits). This type of document is a standard proxy solicitation material sent to shareholders to inform them of an upcoming meeting and request their participation/votes, which falls under the Proxy Solicitation & Information Statement category.
2019-02-19 Korean
기업설명회(IR)개최
Investor Presentation Classification · 98% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, location (Hong Kong and Singapore), purpose (KIS Investors Forum Asia 2019), and the method of engagement (1:1 meetings). Since this is an announcement of an event rather than the presentation slides themselves, and it serves as a regulatory notification of corporate activity, it fits best under the RNS (Regulatory Filings) category as a general regulatory announcement.
2019-02-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.